Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Asuragen Enters Into An Agreement With Biogen Idec To Pursue Drug-Diagnostic Co-Development Strategy

Asuragen, Inc has entered into an agreement with Biogen Idec to identify a potential companion diagnostic test. This test may be used to select patients likely to respond to a Biogen Idec therapeutic candidate in clinical development.

“The integrated drug-diagnostic co-development strategy being pursued by Biogen Idec and Asuragen has enormous potential to help physicians identify patients that will benefit from specific cancer treatments, and will be another step towards delivering on the promise of personalized medicine,” said Matt Winkler, CEO of Asuragen. “We look forward to leveraging our long history and broad expertise in biomarker discovery, pharmacogenomic services, and diagnostic development capabilities for this project.”